<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-W3GDQPF" height="0" width="0" style="display:none;visibility:hidden">

Siste nytt

CRNA

Circio announces circVec LNP-delivery collaboration with Certest progressing to in vivo testing

Certest Biotec, S.L. and Circio are collaborating to create and test circVec DNA-LNP formulations for potential therapeutic applications Certest's proprietary ionizable lipids and their optimized LNP formulations have shown impressive delivery specificity to several tissues of interest to Circio, including lung, liver and spleen Technical formulation and in vitro analysis of circVec-LNP formulations by Certest have been successful, and the collaboration will now progress to in vivo delivery testing

Lytix Biopharma
LYTIX
Børsmelding

Lytix Biopharma AS: Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization

  Oslo, 19 November 2024. Lytix Biopharma ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of tomorrow's cancer treatment, today releases its third quarter 2024 results. Lytix achieved substantial p

ELABS

Elliptic Labs’ Launches for the First Time, Two AI Virtual Smart Sensors, on Lenovo ThinkPad™ X1 Carbon Gen 13 Aura Edition Laptops

Oslo, Norway --- Elliptic Labs (OSE: ELABS), the global leader in AI Virtual Smart Sensors™, today announced the commercial launch of its AI software platform on Lenovo’s ThinkPad X1 Carbon Aura Edition laptop. This premium device release marks the l

Observe Medical
OBSRV
Børsmelding

OBSERVE MEDICAL ASA: Resolutions to increase the share capital in connection with subsequent offering and conditional loan conversion

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY ORINDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANYOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BEUNLAWFUL. THIS ANNO

Observe Medical
OBSRV
Børsmelding

Observe Medical ASA: OBSERVE MEDICAL ASA: Resolutions to increase the share capital in connection with subsequent offering and conditional loan conversion

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS A